Scioto Biosciences is pioneering the development of Activated Bacterial Therapeutics (ABT) aimed at addressing unmet medical needs related to gastrointestinal (GI) disorders and conditions associated with the gut-brain axis, particularly in children and adults with autism spectrum disorder (ASD). Their ABT platform utilizes live bacterial therapeutics that are delivered in a biofilm state, enhancing their persistence and efficacy within the gut. This innovative approach not only aims to improve the microbiome but also targets various disorders linked to "leaky gut," such as Clostridium difficile infections and irritable bowel syndrome. By leveraging the natural abilities of beneficial bacteria, Scioto's technology seeks to provide lasting therapeutic effects and improve overall health outcomes.

The company's recent clinical trials, including a Phase Ib study of SB-121, a specific probiotic formulation, have shown promising results in improving adaptive behavior in participants with autism. SB-121 combines Limosilactobacillus reuteri with dextran microparticles and maltose, enhancing the bacterium's adherence to intestinal cells and its survival through the digestive system. This formulation is designed to stimulate the gut-brain axis, potentially leading to improvements in social behavior and cognitive function. Scioto's commitment to microbiome research and its unique delivery system positions it at the forefront of therapeutic interventions for ASD and related GI disorders, aiming to revolutionize how bacterial therapies are utilized in clinical settings.

United States

Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics. The companies treatment focuses on activating beneficial bacteria to promote healing.

Scioto Biosciences

Company Details